atazanavir has been researched along with saquinavir in 34 studies
| Studies (atazanavir) | Trials (atazanavir) | Recent Studies (post-2010) (atazanavir) | Studies (saquinavir) | Trials (saquinavir) | Recent Studies (post-2010) (saquinavir) |
|---|---|---|---|---|---|
| 75 | 1 | 37 | 1,454 | 256 | 219 |
| Protein | Taxonomy | atazanavir (IC50) | saquinavir (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 1.9 | |
| Bile salt export pump | Homo sapiens (human) | 3.9 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (BRU ISOLATE) | 0.016 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 0.0084 | |
| Gag polyprotein | HIV-1 M:B_MN | 0.0131 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 4.05 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.5 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.0066 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 4.273 | |
| Substance-K receptor | Homo sapiens (human) | 6.214 | |
| Thromboxane-A synthase | Homo sapiens (human) | 2.182 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 4.273 | |
| Mu-type opioid receptor | Homo sapiens (human) | 9.625 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 6.951 | |
| Exoribonuclease H | Human immunodeficiency virus 2 | 0.0005 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 1.9 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 1.9 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 1.9 | |
| Genome polyprotein | Human rhinovirus sp. | 0.0005 | |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | 8.26 | |
| Protease | Human immunodeficiency virus 1 | 0.0217 | |
| Protease | Human immunodeficiency virus 1 | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (52.94) | 29.6817 |
| 2010's | 13 (38.24) | 24.3611 |
| 2020's | 3 (8.82) | 2.80 |
| Authors | Studies |
|---|---|
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Danielson, UH; Shuman, CF; Vrang, L | 1 |
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB | 1 |
| Bertucci, C; Cimitan, S; Danielson, UH; Lindgren, MT | 1 |
| Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX | 1 |
| Agbandje-McKenna, M; Clemente, JC; Coman, RM; Dunn, BM; Goodenow, MM; Govindasamy, L; Janka, LK; Jeung, JA; Leelamanit, W; McKenna, R; Nukoolkarn, S; Thiaville, MM | 1 |
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A | 1 |
| Dandache, S; Parkin, N; Schapiro, JM; Sévigny, G; Stranix, BR; Wainberg, MA; Wu, JJ; Yelle, J | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| Ali, A; Anjum, SG; Cao, H; Nalam, MN; Nathans, RS; Rana, TM; Reddy, GS; Schiffer, CA | 1 |
| Hayashi, H; Mimoto, T; Nojima, S; Shintani, M; Takaku, H; Terashima, K | 1 |
| DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI | 1 |
| Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B | 1 |
| Chen, L; Chen, X; He, Z; Peng, N; Qin, L; You, J | 1 |
| Brynda, J; Cígler, P; Fanfrlík, J; Grantz Sasková, K; Grüner, B; Konvalinka, J; Kozísek, M; Král, V; Lepsík, M; Plesek, J; Pokorná, J; Rezácová, P; Václavíková, J | 1 |
| Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H | 1 |
| Axelsson, L; Ekegren, JK; Hallberg, A; Kihlström, J; Larhed, M; Mahalingam, AK; Samuelsson, B; Unge, T; Wallberg, H; Wannberg, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Amano, M; Anderson, DD; Aoki, M; Das, D; Ghosh, AK; Koh, Y; Kulkarni, S; Mitsuya, H; Tojo, Y | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Cane, PA; Kolli, M; Myers, RE; Parry, CM; Pillay, D; Schiffer, C | 1 |
| Amano, M; Baldridge, A; Chapsal, BD; Ghosh, AK; Koh, Y; Mitsuya, H; Steffey, MP; Walters, DE | 1 |
| Hamburger, M; Hamy, F; Klimkait, T; Louvel, S; Mojarrab, M; Potterat, O; Sanglier, JJ; Vidal, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Agniswamy, J; Ghosh, AK; Louis, JM; Rao, KV; Sayer, JM; Shen, CH; Wang, YF; Weber, IT; Xu, CX | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agniswamy, J; Aoki, M; Bulut, H; Das, D; Ghosh, AK; Hayashi, H; Martyr, CD; Mitsuya, H; Nyalapatla, PR; Osswald, HL; Rao, KV; Wang, YF; Weber, IT | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Brindisi, M; Ghosh, AK; Kovela, S; Mitsuya, H; Osswald, HL; R Nyalapatla, P; Rao, KV; Wang, YF; Weber, IT | 1 |
| Agniswamy, J; Ghosh, AK; Hattori, SI; Hayashi, H; Ho, RY; Mitsuya, H; Simpson, HM; Wang, YF; Weber, IT; Williams, JN | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Ghosh, AK; Kovela, S; Mitsuya, H; Osswald, HL; Wang, YF; Weber, IT | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
3 review(s) available for atazanavir and saquinavir
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
31 other study(ies) available for atazanavir and saquinavir
| Article | Year |
|---|---|
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
Topics: Biosensing Techniques; Cells, Cultured; Cluster Analysis; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Principal Component Analysis; Quantitative Structure-Activity Relationship; Virus Replication | 2004 |
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles | 2005 |
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
Topics: Absorption; Anti-HIV Agents; Antineoplastic Agents; Binding Sites; Biosensing Techniques; Blood Proteins; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Lipids; Membranes, Artificial; Orosomucoid; Serum Albumin; Surface Plasmon Resonance; Taxoids | 2005 |
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides | 2006 |
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Topics: Amino Acid Substitution; Atazanavir Sulfate; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; Hydrophobic and Hydrophilic Interactions; Kinetics; Models, Molecular; Oligopeptides; Polymorphism, Genetic; Pyridines; Structure-Activity Relationship | 2006 |
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication | 2007 |
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Cell Survival; Drug Resistance, Viral; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Mutation; Phenotype; Sulfonamides; Viral Proteins | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
Topics: Cell Line; Dipeptides; Drug Design; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Lopinavir; Models, Molecular; Molecular Structure; Oxazolidinones; Pyrimidinones; Stereoisomerism; Structure-Activity Relationship | 2007 |
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
Topics: Animals; Dogs; Drug Design; Hepatocytes; HIV Protease Inhibitors; HIV-1; Humans; Molecular Structure; Mutation; Phenylbutyrates; Sensitivity and Specificity; Structure-Activity Relationship | 2008 |
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage | 2008 |
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides | 2008 |
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
Topics: Animals; Antimalarials; Atazanavir Sulfate; Chloroquine; Drug Resistance; Drug Synergism; Female; HIV Protease Inhibitors; Humans; In Vitro Techniques; Lopinavir; Malaria; Mice; Nelfinavir; Oligopeptides; Plasmodium chabaudi; Plasmodium falciparum; Pyridines; Pyrimidinones; Ritonavir; Saquinavir | 2008 |
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Topics: Boron Compounds; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Metals; Models, Molecular; Molecular Structure; Mutation | 2008 |
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides | 2009 |
HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Topics: Alcohols; Antiviral Agents; Crystallography, X-Ray; HIV Protease; HIV Protease Inhibitors; HIV-1; Inhibitory Concentration 50; Molecular Mimicry; Mutation, Missense | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Topics: Cell Line; Dimerization; Drug Resistance, Multiple, Viral; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Macrocyclic Compounds; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Virus Replication | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
Topics: Cell Line; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; gag Gene Products, Human Immunodeficiency Virus; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Virus Replication | 2011 |
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
Topics: Carbamates; Catalytic Domain; Cell Line; Crystallography, X-Ray; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Protein Binding; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2011 |
Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Daphne; Diterpenes; Heterocyclic Compounds, 4 or More Rings; Mediterranean Region; Molecular Structure; Receptors, CXCR4 | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
Topics: Binding Sites; Calorimetry, Differential Scanning; Carbamates; Crystallization; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; Escherichia coli; Furans; Genes, Synthetic; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Pyrrolidinones; Structure-Activity Relationship; Sulfonamides | 2013 |
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
Topics: Benzothiazoles; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Docking Simulation; Pyrans; Structure-Activity Relationship; Sulfonamides | 2017 |
Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
Topics: Catalytic Domain; Crystallography, X-Ray; Drug Design; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Molecular Structure; Protein Conformation; Stereoisomerism; Structure-Activity Relationship | 2018 |
Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.
Topics: Catalytic Domain; Chemistry Techniques, Synthetic; Drug Design; HIV Protease; HIV Protease Inhibitors; HIV-1; Ligands; Models, Molecular; Oxazolidinones; Stereoisomerism; Structure-Activity Relationship | 2018 |
Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
Topics: Amino Acid Substitution; Catalytic Domain; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Furans; Heterocyclic Compounds, Bridged-Ring; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Protein Binding; Stereoisomerism | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |